{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:56:46Z","timestamp":1774954606504,"version":"3.50.1"},"reference-count":83,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Colombiana de Psiquiatr\u00eda"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.rcp.2018.07.002","type":"journal-article","created":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T07:23:20Z","timestamp":1535873000000},"page":"84-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["High Doses of Drugs Extensively Metabolized by CYP3A4 Were Needed to Reach Therapeutic Concentrations in Two Patients Taking Inducers"],"prefix":"10.1016","volume":"49","author":[{"given":"Nitin","family":"Chopra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Can-Jun","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betsy","family":"McCollum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy","family":"Ognibene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"de Leon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rcp.2018.07.002_bib0420","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00210-003-0815-3","article-title":"Cytochrome P450 3A and their regulation","volume":"369","author":"Burk","year":"2004","journal-title":"Naunyn Schmiedebergs Arch Pharmacol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0425","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1172\/JCI34007","article-title":"Gut instincts: CYP3A4 and intestinal drug metabolism","volume":"117","author":"Thummel","year":"2007","journal-title":"J Clin Invest."},{"key":"10.1016\/j.rcp.2018.07.002_bib0430","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00228-007-0393-2","article-title":"The limited impact of CYP3A5 genotype for the pharmacokinetics of CYP3A substrates","volume":"63","author":"Burk","year":"2007","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0435","series-title":"A practitioner's guide for prescribing antiepileptics and mood stabilizers for adults with intellectual disabilities.","author":"de Leon","year":"2012"},{"key":"10.1016\/j.rcp.2018.07.002_bib0440","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/0006-2952(94)90071-X","article-title":"Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation","volume":"47","author":"Kerr","year":"1994","journal-title":"Biochem Pharmacol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0445","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1124\/jpet.104.073114","article-title":"N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7","volume":"311","author":"Staines","year":"2004","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.rcp.2018.07.002_bib0450","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs\u2014best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.rcp.2018.07.002_bib0455","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.phrs.2016.02.014","article-title":"Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics","volume":"106","author":"Spina","year":"2016","journal-title":"Pharmacol Res."},{"key":"10.1016\/j.rcp.2018.07.002_bib0460","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.rpsm.2014.10.005","article-title":"The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part II: Pharmacological issues and further understanding","volume":"8","author":"de Leon","year":"2015","journal-title":"Rev Psiquiatr Salud Ment."},{"key":"10.1016\/j.rcp.2018.07.002_bib0465","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.rpsm.2014.10.006","article-title":"The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: A summary of the current state for clinicians","volume":"8","author":"de Leon","year":"2015","journal-title":"Rev Psiquiatr Salud Ment."},{"key":"10.1016\/j.rcp.2018.07.002_bib0470","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry."},{"key":"10.1016\/j.rcp.2018.07.002_bib0475","unstructured":"Lexicomp. Drug information handbook. 23rd ed. Hudson: Lexi-Comp, Inc.; 2014."},{"key":"10.1016\/j.rcp.2018.07.002_bib0480","first-page":"1215","article-title":"SCN1A and SCN1B gene polymorphisms and their association with plasma concentrations of carbamazepine and carbamazepine 10, 11 epoxide in Iranian epileptic patients","volume":"18","author":"Namazi","year":"2015","journal-title":"Iran J Basic Med Sci."},{"key":"10.1016\/j.rcp.2018.07.002_bib0485","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2125.1994.tb04336.x","article-title":"Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms","volume":"38","author":"Andersson","year":"1994","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0490","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00004714-199608000-00001","article-title":"Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans","volume":"16","author":"Schmider","year":"1996","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0495","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000028398","article-title":"The CYP2C19 enzyme polymorphism","volume":"61","author":"Wedlund","year":"2000","journal-title":"Pharmacology."},{"key":"10.1016\/j.rcp.2018.07.002_bib0500","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.coph.2005.04.003","article-title":"Treatment options for status epilepticus","volume":"5","author":"Lowenstein","year":"2005","journal-title":"Curr Opin Pharmacol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0505","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2125.1977.tb00666.x","article-title":"Plasma concentrations of benzodiazepines","volume":"4","author":"Bond","year":"1977","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0510","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2125.1978.tb01684.x","article-title":"Plasma concentrations of diazepam and desmethyldiazepam during chronic diazepam therapy","volume":"6","author":"Rutherford","year":"1978","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0515","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004714-200102000-00016","article-title":"The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine","volume":"21","author":"Wong","year":"2001","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0520","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2125.2005.02507.x","article-title":"Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics","volume":"61","author":"Grimm","year":"2006","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0525","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/00007691-200410000-00005","article-title":"Quetiapine serum concentrations in psychiatric patients: the influence of comedication","volume":"26","author":"Hasselstr\u00f8m","year":"2004","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.rcp.2018.07.002_bib0530","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.4088\/JCP.v68n1011","article-title":"Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service","volume":"68","author":"Castberg","year":"2007","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rcp.2018.07.002_bib0535","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/1874241600801010017","article-title":"Therapeutic drug monitoring of quetiapine: effect of coadministration with antiepileptic drugs in patients with psychiatric disorders","volume":"1","author":"Santoro","year":"2008","journal-title":"Open Clin Chem J."},{"key":"10.1016\/j.rcp.2018.07.002_bib0540","first-page":"203","article-title":"Individual clearance and therapeutic drug monitoring of quetiapine in clinical practice","volume":"31","author":"Wittmann","year":"2010","journal-title":"Neuro Endocrinol Lett."},{"key":"10.1016\/j.rcp.2018.07.002_bib0545","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/17425255.2016.1154043","article-title":"Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics","volume":"12","author":"Spina","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0550","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/WNF.0b013e31816a1cc6","article-title":"Drug interaction can lead to undetectable serum concentrations of quetiapine in the presence of carbamazepine","volume":"32","author":"Nickl-Jockschat","year":"2009","journal-title":"Clin Neuropharmacol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0555","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/JCP.0000000000000401","article-title":"A case report that suggested that the patient was very sensitive to induction and needed 1600mg\/d of lamotrigine to get therapeutic concentrations","volume":"35","author":"Jackson","year":"2015","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0560","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0006-3223(97)00190-X","article-title":"Multiple fixed doses of \u201cSeroquel\u201d (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo","volume":"42","author":"Arvanitis","year":"1997","journal-title":"Biol Psychiatry."},{"key":"10.1016\/j.rcp.2018.07.002_bib0565","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/00023210-199809040-00007","article-title":"Quetiapine: a review of its use in schizophrenia","volume":"9","author":"Gunasekara","year":"1998","journal-title":"CNS Drugs."},{"key":"10.1016\/j.rcp.2018.07.002_bib0570","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1176\/appi.psy.49.4.347","article-title":"A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part II","volume":"49","author":"de Leon","year":"2008","journal-title":"Psychosomatics."},{"key":"10.1016\/j.rcp.2018.07.002_bib0575","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4088\/JCP.v58n1010b","article-title":"Risperidone and cytochrome P450 3A","volume":"58","author":"de Leon","year":"1997","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rcp.2018.07.002_bib0580","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4088\/JCP.v60n0709","article-title":"A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A","volume":"60","author":"Bork","year":"1999","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rcp.2018.07.002_bib0585","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/00007691-200008000-00019","article-title":"Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate","volume":"22","author":"Spina","year":"2000","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.rcp.2018.07.002_bib0590","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00213-002-1056-8","article-title":"Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes","volume":"162","author":"Ono","year":"2002","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.rcp.2018.07.002_bib0595","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/00004714-200102000-00020","article-title":"Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity","volume":"21","author":"Spina","year":"2001","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0600","first-page":"1263","article-title":"Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes","volume":"29","author":"Yasui-Furukori","year":"2001","journal-title":"Drug Metab Dispos."},{"key":"10.1016\/j.rcp.2018.07.002_bib0605","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/JCP.0b013e318058244d","article-title":"The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19","volume":"27","author":"de Leon","year":"2007","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0610","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/17512433.2017.1345623","article-title":"A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone","volume":"10","author":"Schoretsanitis","year":"2017","journal-title":"Expert Rev Clin Pharmacol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0615","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1124\/dmd.107.018275","article-title":"Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans","volume":"36","author":"Vermeir","year":"2008","journal-title":"Drug Metab Dispos."},{"key":"10.1016\/j.rcp.2018.07.002_bib0620","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2174\/138920010791636202","article-title":"Atypical antipsychotic metabolism and excretion","volume":"11","author":"Sheehan","year":"2010","journal-title":"Curr Drug Metab."},{"key":"10.1016\/j.rcp.2018.07.002_bib0625","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-2007-973836","article-title":"A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels","volume":"40","author":"Leon Jd","year":"2007","journal-title":"Pharmacopsychiatry."},{"key":"10.1016\/j.rcp.2018.07.002_bib0630","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0033-3182(10)70664-2","article-title":"The pharmacokinetics of paliperidone versus risperidone","volume":"51","author":"de Leon","year":"2010","journal-title":"Psychosomatics."},{"key":"10.1016\/j.rcp.2018.07.002_bib0635","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cpdd.122","article-title":"Effect of carbamazepine on the pharmacokinetics of paliperidone extended-release tablets at steady-state","volume":"3","author":"Kerbusch-Herben","year":"2014","journal-title":"Clin Pharmacol Drug Dev."},{"key":"10.1016\/j.rcp.2018.07.002_bib0640","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/FTD.0b013e3182966c2f","article-title":"Interaction between paliperidone and carbamazepine","volume":"35","author":"Yasui-Furukori","year":"2013","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.rcp.2018.07.002_bib0645","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00228-010-0812-7","article-title":"Serum concentrations of paliperidone versus risperidone and clinical effects","volume":"66","author":"Nazirizadeh","year":"2010","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0650","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00007691-199902000-00013","article-title":"Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication","volume":"21","author":"Olesen","year":"1999","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.rcp.2018.07.002_bib0655","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/00007691-200208000-00009","article-title":"Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication","volume":"24","author":"Linnet","year":"2002","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.rcp.2018.07.002_bib0660","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1742-7843.2007.00017.x","article-title":"Metabolic drug interactions with newer antipsychotics: a comparative review","volume":"100","author":"Spina","year":"2007","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0665","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.pnpbp.2008.04.018","article-title":"Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model","volume":"32","author":"Botts","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"10.1016\/j.rcp.2018.07.002_bib0670","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/FTD.0b013e3181c0590e","article-title":"Effect of valproate on olanzapine plasma concentrations in patient with bipolar or schizoaffective disorder","volume":"31","author":"Spina","year":"2009","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.rcp.2018.07.002_bib0675","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ridd.2008.10.010","article-title":"Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities","volume":"30","author":"de Leon","year":"2009","journal-title":"Res Dev Disabil."},{"key":"10.1016\/j.rcp.2018.07.002_bib0680","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00007691-200302000-00007","article-title":"Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication","volume":"25","author":"Gex-Fabry","year":"2003","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.rcp.2018.07.002_bib0685","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00007691-200108000-00015","article-title":"Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service","volume":"23","author":"Weigmann","year":"2001","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.rcp.2018.07.002_bib0690","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00702-014-1300-5","article-title":"Clinical applications of CYP genotyping in psychiatry","volume":"122","author":"Spina","year":"2015","journal-title":"J Neural Transm (Vienna)."},{"key":"10.1016\/j.rcp.2018.07.002_bib0695","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1017\/S1461145703003249","article-title":"Glucuronidation enzymes, genes and psychiatry","volume":"6","author":"de Leon","year":"2003","journal-title":"Int J Neuropsychopharmacol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0700","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2125.1994.tb04385.x","article-title":"Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test","volume":"38","author":"Bertilsson","year":"1994","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0705","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1177\/00912700122010717","article-title":"Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations","volume":"41","author":"Olesen","year":"2001","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0710","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1111\/j.1476-5381.2009.00330.x","article-title":"Bioavailability of diazepam after intramuscular injection of its water-soluble prodrug alone or with atropine-pralidoxime in healthy volunteers","volume":"157","author":"Abbara","year":"2009","journal-title":"Br J Pharmacol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0715","unstructured":"US Package insert of quetiapine. Available from: http:\/\/dailymed.nlm.nih.gov\/dailymed\/search.cfm?labeltype=all&query=QUETIAPINE+FUMARATE&pagesize=20&page=1."},{"key":"10.1016\/j.rcp.2018.07.002_bib0720","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0278-5846(03)00148-9","article-title":"Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report","volume":"27","author":"de Leon","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"10.1016\/j.rcp.2018.07.002_bib0725","first-page":"5428","article-title":"Three patients needing high doses of valproic Acid to get therapeutic concentrations","volume":"2015","author":"Jackson","year":"2015","journal-title":"Case Rep Psychiatry."},{"key":"10.1016\/j.rcp.2018.07.002_bib0730","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/schbul\/sbq042","article-title":"Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons","volume":"38","author":"Rummel-Kluge","year":"2012","journal-title":"Schizophr Bull."},{"key":"10.1016\/j.rcp.2018.07.002_bib0735","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4103\/0253-7613.71896","article-title":"Acute akathisia with quetiapine: A case report and review of literature","volume":"42","author":"Shah","year":"2010","journal-title":"Indian J Pharmacol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0740","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ridd.2005.05.002","article-title":"Guidelines for the use of clozapine in individuals with developmental disabilities","volume":"27","author":"Sabaawi","year":"2006","journal-title":"Res Dev Disabil."},{"key":"10.1016\/j.rcp.2018.07.002_bib0745","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1192\/bjp.174.2.93","article-title":"The demise of the published case report\u2014is resuscitation necessary?","volume":"174","author":"Farmer","year":"1999","journal-title":"Br J Psychiatry."},{"key":"10.1016\/j.rcp.2018.07.002_bib0750","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/JCP.0b013e3182a4ea8f","article-title":"A case report that suggested that aspirin's effects on valproic acid metabolism may contribute to valproic acid's inducer effects on clozapine metabolism","volume":"33","author":"Riesselman","year":"2013","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0755","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00115-002-1310-7","article-title":"Tolerance of high dosage carbamazepine monotherapy in treatment of epilepsy","volume":"73","author":"Bauer","year":"2002","journal-title":"Nervenarzt."},{"key":"10.1016\/j.rcp.2018.07.002_bib0760","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/archpsyc.55.11.1048","article-title":"Very high cytochrome P4501A2 activity and nonresponse to clozapine","volume":"55","author":"Bender","year":"1998","journal-title":"Arch Gen Psychiatry."},{"key":"10.1016\/j.rcp.2018.07.002_bib0765","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/01.jcp.0000116646.91923.2f","article-title":"Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene","volume":"24","author":"Eap","year":"2004","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0770","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/00004714-200112000-00011","article-title":"Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C>A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine","volume":"21","author":"Ozdemir","year":"2001","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0775","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/YCT.0b013e3181a2f867","article-title":"Very high-dose clozapine and electroconvulsive therapy combination treatment in a patient with schizophrenia","volume":"25","author":"Keller","year":"2009","journal-title":"J ECT."},{"key":"10.1016\/j.rcp.2018.07.002_bib0780","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/0269881108089819","article-title":"Clozapine: more than 900 mg\/day may be needed","volume":"23","author":"Maccall","year":"2009","journal-title":"J Psychopharmacol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0785","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.schres.2014.09.020","article-title":"Use of very-high-dose olanzapine in treatment-resistant schizophrenia","volume":"159","author":"Batail","year":"2014","journal-title":"Schizophr Res."},{"key":"10.1016\/j.rcp.2018.07.002_bib0790","first-page":"109","article-title":"Diazepam (valium) very high dosage: longitudinal and single case study","volume":"7","author":"Ditman","year":"1966","journal-title":"West Med Med J West."},{"key":"10.1016\/j.rcp.2018.07.002_bib0795","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.4088\/JCP.v63n1116g","article-title":"High degree of tolerability for monotherapy with high doses of quetiapine: a case report","volume":"63","author":"Bobes","year":"2002","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rcp.2018.07.002_bib0800","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/13651500510014765","article-title":"Efficacy safety and tolerability of quetiapine: short-term high doses with long-term follow-up","volume":"9","author":"Nagy","year":"2005","journal-title":"Int J Psychiatry Clin Pract."},{"key":"10.1016\/j.rcp.2018.07.002_bib0805","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.schres.2008.01.013","article-title":"Quetiapine at high doses for the treatment of refractory schizophrenia","volume":"101","author":"Boggs","year":"2008","journal-title":"Schizophr Res."},{"key":"10.1016\/j.rcp.2018.07.002_bib0810","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11126-012-9248-9","article-title":"Use of high doses of quetiapine in bipolar disorder episodes are not linked to high activity of cytochrome P4503A4 and\/or cytochrome P4502D6","volume":"84","author":"Khazaal","year":"2013","journal-title":"Psychiatr Q."},{"key":"10.1016\/j.rcp.2018.07.002_bib0815","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.schres.2004.07.014","article-title":"High-dose quetiapine in treatment refractory schizophrenia","volume":"73","author":"Pierre","year":"2005","journal-title":"Schizophr Res."},{"key":"10.1016\/j.rcp.2018.07.002_bib0820","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.schres.2015.01.042","article-title":"Caffeine consumption in a long-term psychiatric hospital: Tobacco smoking may explain in large part the apparent association between schizophrenia and caffeine use","volume":"164","author":"Arrojo-Romero","year":"2015","journal-title":"Schizophr Res."},{"key":"10.1016\/j.rcp.2018.07.002_bib0825","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/JCP.0000000000000093","article-title":"False-negative studies may systematically contaminate the literature on the effects of inducers in neuropsychopharmacology. Part I: focus on epilepsy","volume":"34","author":"de Leon","year":"2014","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rcp.2018.07.002_bib0830","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/JCP.0000000000000115","article-title":"False-negative studies may systematically contaminate the literature on the effects of inducers in neuropsychopharmacology: part II: focus on bipolar disorder","volume":"34","author":"de Leon","year":"2014","journal-title":"J Clin Psychopharmacol."}],"container-title":["Revista Colombiana de Psiquiatr\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0034745018300726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0034745018300726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:20:21Z","timestamp":1758518421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0034745018300726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":83,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0034745018300726"],"URL":"https:\/\/doi.org\/10.1016\/j.rcp.2018.07.002","relation":{},"ISSN":["0034-7450"],"issn-type":[{"value":"0034-7450","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High Doses of Drugs Extensively Metabolized by CYP3A4 Were Needed to Reach Therapeutic Concentrations in Two Patients Taking Inducers","name":"articletitle","label":"Article Title"},{"value":"Revista Colombiana de Psiquiatr\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rcp.2018.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Asociaci\u00f3n Colombiana de Psiquiatr\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}